Reagents and instruments for immunology, cell biology and molecular biology.
 

Abbexa

 

Abbexa is a dedicated worldwide supplier of biological tools for the life science, pharmaceutical and biotechnology research and development sectors. Abbexa provides the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools designed for use in research. Abbexa also offers custom protein, peptide and antibody production services to meet customer requirements.

Abbexa is committed to providing scientists and researchers with the best customer experience and high-quality products.

Abbexa’s mission is to offer unrivalled expertise and outstanding quality laboratory consumable products, striving to consistently improve. Please do get in touch with any comments regarding the website, service, products, or anything else.

 

Learn more :

 

 

  

  

 

 

         

   

  

Antibodies for Cancer Research

     

Cell Biology Antibodies

    

ELISA Kits for Accurate Detection

   Primary Antibodies
             

 

 

Website : www.abbexa.com
 
 
> Abbexa > Products for research > COVID-19 > SARS-CoV-2 - Therapeutic Candidates for Research and Development > SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates
SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates

SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates


Ruxolitinib, whose commercial name is Jakavi, is a tyrosine kinase inhibitor and more specifically Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are JAK-targeting tyrosine kinases.  Ruxolitinib is used for the treatment of certain myeloproliferative syndromes such as myelofibrosis. It is also used for the treatment of Vaquez disease (essential polyglobulia or polycythemia vera or rubra), characterized by polyglobulia and an increase in total blood cell volume.
The Novartis group, which markets Jakavi, began studying the effects of this drug on Covid-19 caused by SARS-CoV-2. The purpose of this clinical study is to determine whether ruxolitinib could mitigate the potential complications of Covid-19 and involves patients with Covid-19-related cytokine shock. This Phase III clinical study is based on the fact that the JAK-STAT pathway is fundamental to many biological processes related to immunity and inflammation, including the mobilization of a cytokine response.

Search result : 2 product found

Refine your search :

RUOCE / IVD
  • Biochemicals 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
abx076799-25mg
Ruxilitinib
 25mg 
abx076799-5mg
Ruxilitinib
 5mg 
    ‹
    ›